Back in August of 2020, health and fitness influencer Ben Greenfield provided animal-based diet proponent Dr. Paul Saladino a platform to discuss his dietary ideology via a guest-hosting solo episode on his popular podcast. A primary feature was Paul breaking down the perils, as he framed it, of phytochemicals. In this episode, I focus primarily on correcting the misinformation Paul presented on the phytochemical sulforaphane.

You can listen to Dr. Paul Saladino’s episode on Ben Greenfield’s podcast here.

Studies cited by Paul:

Study 1

Study 2

Study 3

Studies I cite on the benefits and benign nature of sulforaphane:

Study 1

Study 2

Study 3

There's so much talk about taking GLP-1 these days. But how does our bodies' own GLP-1 work? And how do you know if your GLP-1 levels are suboptimal? I dig into this very subject as well as how to restore your body's own GLP-1 function.

I also uncover the health implications - particularly blood sugar dysregulation - of low GLP-1 and how GLP-1 function is often the very first domino to fall on the path to diabetes.

I first discussed GLP-1 back in early 2020, before semaglutide was widely available on the market as a weight-loss drug, in an episode titled Blood Sugar Physiology 101. Listen to it here for a detailed explanation of the body's Phase 1 insulin response and its relationship to GLP-1.

In this episode, I give my take on GLP-1 analogs (Ozempic, Mounjaro, etc.). I talk about the benefits, the potential risks that are rarely spoken about and the likely long-term limitations. I get into how these compounds differ from the GLP-1 we make on our own as well as ways to leverage that natural secretion for health benefits. I also dispel the notion that the "natural" GLP-1 stimulators are even remotely on par with the drugs on the market.